Sara Veneziano

Dr. Sara Veneziano

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LFLorenzo Flori
Lorenzo Flori
SVSara Veneziano
Sara Veneziano
Alma MartelliAlma Martelli
Alma Martelli
EPEUGENIA PIRAGINE
EUGENIA PIRAGINE
VCVincenzo Calderone
Vincenzo Calderone
The transsulfuration pathway plays a central role in the regulation of sulfur metabolism and contributes to the maintenance of cellular homeostasis. Starting from homocysteine, a sulfur-containing amino acid derived from methionine via the methionine cycle, this metabolic pathway supports the biosynthesis of cysteine and other downstream products, such as taurine, serine, reduced glutathione and the gasotransmitter hydrogen sulfide (H2S). The most common disruption of this pathway leads to hyperhomocysteinemia (HHcy), a well-known risk factor for the development of cardiometabolic diseases and other pathological conditions. In this context, identifying effective pharmacological strategies is crucial. Based on both preclinical and clinical evidence, this review provides an updated overview on the role of folates in restoring transsulfuration balance in HHcy and explores the potential effects of downstream products (such as serine, taurine, and precursors of glutathione) under HHcy conditions. Finally, it examines the pharmacological properties of H2S-donors in cultured cells exposed to HHcy and in animal models of HHcy. This summary of the literature offers new perspectives for the treatment of HHcy and the prevention of its associated multiorgan complications.

25 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EPEUGENIA PIRAGINE
EUGENIA PIRAGINE
SVSara Veneziano
Sara Veneziano
STSabrina Trippoli
Sabrina Trippoli
Andrea MessoriAndrea Messori
Andrea Messori
VCVincenzo Calderone
Vincenzo Calderone
Background/Objectives: The incidence and prevalence of tricuspid regurgitation (TR) are increasing worldwide. “Traditional” drug therapy with diuretics is often ineffective and the identification of new strategies, including non-pharmacological ones, is an urgent need. The aim of this study was to summarize the results on the efficacy and safety of Cardioband, one of the few approved transcatheter tricuspid valve repair systems, in patients with TR. Methods: Three databases (Medline, Scopus, and CENTRAL) were searched to identify clinical trials and observational studies on the efficacy (primary outcome) and safety (secondary outcome) of Cardioband. A random-effects meta-analysis was performed with R software (version 4.3.3). Survival and freedom from heart failure (HF) hospitalization were estimated with the method of reconstructing individual patient data from Kaplan–Meier curves (IPDfromKM). Results: Eleven studies were included in this systematic review and meta-analysis. Cardioband significantly reduced annulus diameter (−9.31 mm [95% Confidence Interval, CI: −11.47; −7.15]), vena contracta (−6.41 mm [95% CI: −8.34; −4.49]), and effective regurgitant orifice area (EROA) (−0.50 cm2 [95% CI: −0.72; −0.28]) in patients with TR. Cardioband reduced the severity of TR and the extent of heart failure in 91% [95% CI: 85; 97] and 63% [95% CI: 52–75] of patients, respectively. Finally, Cardioband implantation was associated with prolonged survival and freedom from HF hospitalization (80.1% and 57.8% at 24 months, respectively). Conclusions: This study demonstrates that Cardioband implantation leads to cardiac remodeling and mechanical improvements, reduces the severity of TR, and improves quality of life. Therefore, Cardioband is an effective option for the non-pharmacological treatment of TR.

3 February 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Andrea MessoriAndrea Messori
Andrea Messori
STSabrina Trippoli
Sabrina Trippoli
EPEUGENIA PIRAGINE
EUGENIA PIRAGINE
SVSara Veneziano
Sara Veneziano
VCVincenzo Calderone
Vincenzo Calderone
Background: In unresectable pleural mesothelioma, pemetrexed+cisplatin as first line is considered the standard of care, but novel treatments have been recently proposed. Methods: Our objective was to compare, albeit indirectly, the results of randomized controlled trials on overall survival (OS). The IPDfromKM method was employed for reconstruct individual patient data (IPD) from the graphs of Kaplan–Meier curves. Cox statistics was run to estimate hazard ratios (HRs). Results: After a literature search on Medline (via PubMed) and Scopus databases, six randomized controlled trials were identified in which five new treatments (nivolumab plus ipilimumab, bevacizumab plus pemetrexed plus cisplatin, chemotherapy plus pembrolizumab, ONCOS-102 plus pemetrexed plus cisplatin/carboplatin and cediranib plus pemetrexed+cisplatin with maintenance with cediranib) were evaluated. In five trials, pemetrexed plus cisplatin was the standard of care given to the control arms. Nivolumab plus ipilimumab, bevacizumab plus pemetrexed plus cisplatin and chemotherapy plus pembrolizumab showed a significantly better OS compared with controls. ONCOS-102 plus pemetrexed plus cisplatin/carboplatin did not significantly improve OS. In contrast, OS worsened with cisplatin alone and with cediranib plus pemetrexed+cisplatin with maintenance with cediranib. Discussion: Our analysis indicates that, in patients with unresectable pleural mesothelioma, three of the five novel treatments provided a significant survival benefit compared with the standard of care. Further research is needed to confirm the OS benefit found in our analysis with some treatments, whereas cisplatin alone and cediranib plus pemetrexed+cisplatin with maintenance with cediranib do not seem to deserve further research.

2 February 2025 in Methods and Protocols
Verified
Journal Article
Open access
PDF file
EPEUGENIA PIRAGINE
EUGENIA PIRAGINE
STSabrina Trippoli
Sabrina Trippoli
SVSara Veneziano
Sara Veneziano
Andrea MessoriAndrea Messori
Andrea Messori
VCVincenzo Calderone
Vincenzo Calderone
The IPDfromKM method, or Shiny method, is an artificial intelligence tool that enables indirect comparisons between studies by reconstructing individual patient data (IPD) from Kaplan–Meier (KM) curves. The IPDfromKM method is generally used for superiority analyses, but a further application could be represented by non-inferiority analyses. However, there are no studies supporting this methodological hypothesis. The aim of this work was to validate the IPDfromKM method for non-inferiority analyses by “exploiting” the well-described non-inferiority of implantable devices occluding the left atrial appendage compared to oral anticoagulants in patients with atrial fibrillation. We performed a systematic review searching for randomized controlled trials (RCTs) in the PubMed database and found five studies. The R software (version 4.3.3) was used to perform a standard survival analysis comparing Watchman and Amlet devices with warfarin. The hazard ratio (HR), with 95% confidence interval (CI), was the main parameter of our analysis. The results confirmed the non-inferiority of Amlet and Watchman compared to warfarin (HR of Watchman vs. warfarin: 1.23, 95% CI 0.80 to 1.9; HR of Amlet vs. warfarin: 1.05, 95% CI 0.61 to 1.80). Therefore, we proposed a new application of the IPDfromKM method that could be potentially relevant in decision-making for the management of this common cardiac arrhythmia and a wide range of other pathological conditions.

15 August 2025 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
SVSara Veneziano
Sara Veneziano
STSabrina Trippoli
Sabrina Trippoli
Andrea MessoriAndrea Messori
Andrea Messori
VCVincenzo Calderone
Vincenzo Calderone
EPEUGENIA PIRAGINE
EUGENIA PIRAGINE
Medical devices for tricuspid regurgitation have emerged as viable treatment options for patients who do not respond to drug therapy or who are unsuitable for open-heart surgery due to high surgical risk. Recently, numerous new medical devices have been proposed and approved for use. Therefore, comprehensive reviews of the literature on the current medical devices for tricuspid regurgitation are necessary. This paper subsequently describes all medical devices used for transcatheter tricuspid valve interventions, providing an updated overview of the current options for managing tricuspid regurgitation, a common valvular heart disease associated with changes in the configuration and function of the tricuspid valve. Over 70 million people worldwide suffer from tricuspid regurgitation, with an estimated mortality rate of 0.51 deaths per 10,000 person-years. However, delays in diagnosis and treatment frequently contribute to disease progression. Meanwhile, the growing health and economic burden of tricuspid regurgitation has led to the urgent need for new therapeutic strategies to overcome the limitations of pharmacological and surgical approaches. In this scenario, transcatheter tricuspid valve interventions represent a promising option for patients with severe tricuspid regurgitation, considered inoperable due to excessive surgical risk. Medical devices designed for these innovative approaches are classified into two main groups: transcatheter tricuspid valve repair and replacement systems. This review presents the technological characteristics of medical devices and the results of studies on their clinical efficacy and safety, thereby supporting the use of transcatheter tricuspid valve repair/replacement systems in clinical practice.

10 October 2025 in Pharmacological Research
Verified
Journal Article
Open access
EPEUGENIA PIRAGINE
EUGENIA PIRAGINE
Ersilia LucenteforteErsilia Lucenteforte
Ersilia Lucenteforte
SVSara Veneziano
Sara Veneziano
VCVincenzo Calderone
Vincenzo Calderone
Alma MartelliAlma Martelli
Alma Martelli
Transthyretin amyloidosis (ATTR) is an infiltrative disease caused by the deposition of misfolded transthyretin (TTR) fibrils in organs and tissues, with incidence and prevalence rapidly increasing worldwide. Current therapeutic strategies fall into two main classes: TTR stabilizers and TTR gene silencers. To date, no comprehensive reviews cover all the available pharmacological treatments for ATTR, both approved and off-label. In addition, previous meta-analyses have often excluded real-world data and have not evaluated safety outcomes. In this Grading of Recommendations Assessment Development and Evaluation (GRADE)-assessed meta-analysis, interventional and observational studies were searched in four databases (MEDLINE, Scopus, Embase, and CENTRAL), and 28 studies were included. The use of TTR stabilizers and gene silencers significantly reduces the risk of all-cause mortality compared with placebo (relative risk, RR: 0.70 [95% confidence interval, CI: 0.60-0.83]) in patients with cardiomyopathy, with no differences between drug classes. In observational studies, TTR stabilizers were associated with an even greater reduction in mortality risk (RR: 0.23 [95% CI: 0.12-0.44] and an approximately 37% increase in overall survival probability compared with unexposed patients, estimated using individual patient data from Kaplan-Meier (IPDfromKM) method. These pharmacological treatments also improved nutritional status and quality of life. Overall, they were safe and well tolerated, with no increased risk of adverse events (AEs) or treatment discontinuation due to AEs. In conclusion, this is the first meta-analysis integrating both clinical and real-world data to evaluate efficacy and safety of all available drugs for ATTR, including off-label use. This approach facilitates healthcare decision-making and paves the way for future research.